Analisi di budget impact di anakinra nel trattamento della Malattia di Still in Italia

BACKGROUND: Anakinra, canakinumab and tocilizumab are all effective alternative treatment choice in patients with Still’s disease including both systemic juvenile idiopathic arthritis (SJIA) and adult onset Still’s disease (AOSD). OBJECTIVE: Aim of this study was to estimate the budget impact of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ravasio, Roberto, Giacomelli, Roberto, Bianchi, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AboutScience 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677608/
https://www.ncbi.nlm.nih.gov/pubmed/36627970
http://dx.doi.org/10.33393/grhta.2020.2140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677608/
https://www.ncbi.nlm.nih.gov/pubmed/36627970
http://dx.doi.org/10.33393/grhta.2020.2140

Ejemplares similares